Anti-cat IgG monoclonal antibody or antigen-binding fragment thereof and application thereof

By preparing and screening anti-cat IgG monoclonal antibodies, the problem of lack of anti-cat IgG monoclonal antibodies in the prior art was solved, and the preparation of high-purity antibodies was achieved, which reduced the background of ELISA detection, enhanced specific signals, and made cats Immunological research provides more accurate detection tools.

CN118599004BInactive Publication Date: 2024-11-26SHANGHAI VETERINARY RESEARCH INSTITUTE CAAS (CHINESE ANIMAL HEALTH & EPIDEMIOLOGY CENTER SHANGHAI BRANCH)
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410746821.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-11
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of anti-cat IgG monoclonal antibodies in the prior art has led to cross-reactions and false positive misjudgment in traditional indirect ELISA detection, mainly due to high background problems caused by impurity in the design of secondary antibodies and unclear animal immune background.

Method used

By preparing and screening anti-cat IgG monoclonal antibodies, including isolation and purification of cat IgG, immunization of BALB/C mice, fusion hybridoma cells, screening hybridoma cells, hybridoma cell cloning, preparation of monoclonal antibody, detection of monoclonal antibody Title, specifically bound murine anti-cat IgG monoclonal antibody FG69 was obtained, which was used to reduce the background of the reaction system and to amplify specific signals.

Benefits of technology

The preparation of high-purity anti-cat IgG monoclonal antibodies was achieved, which significantly reduced the background of ELISA detection, enhanced specific binding signals, provided more accurate and sensitive detection results, laying the foundation for cat immunology research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118599004B_ABST
    Figure CN118599004B_ABST
Patent Text Reader

Abstract

The present invention relates to anti-cat IgG monoclonal antibodies and their applications, and discloses a monoclonal antibody or antigen-binding fragment that specifically binds to cat IgG, a multi-specific antigen-binding molecule, a nucleic acid fragment, a vector, a host cell, a preparation method, a pharmaceutical composition, and pharmaceutical uses. The experimental results show that the antibody has better binding activity than the previously obtained antibodies, provides antibodies for cat immunological detection, and lays a foundation for research on related virology, immunology, etc. with cats as the subject.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of antibody preparation in biotechnology, and particularly relates to an anti-cat IgG monoclonal antibody or an antigen binding fragment thereof and application thereof. Background Art

[0002] In the defense system of humans and animals, specific immunity plays a key role, and humoral immunity occupies a certain position in specific immunity. The antibody molecules that play an important role in humoral immunity are mainly immunoglobulins, and the early immune antibody molecules of immune response are mainly IgM, and then gradually type conversion is IgG, these specific molecules not only play the role of resisting foreign pathogens, but also become "evidence" of the effects of these pathogens, therefore, antibodies for different pathogens are important research contents in medicine and veterinary medicine. Detection antibodies need to have certain systems and methods, but its core is biological materials, especially labeled antibodies for different immunoglobulins. Among them, monoclonal antibodies have become the conventional alternative materials of such labeled antibodies because of their advantages such as strong specificity, good homogeneity, and sustainable production.

[0003] The disadvantage of traditional indirect ELISA is the possibility of cross-reaction, which is manifested as high background and easy to cause false positive misjudgment. The reason is that in addition to excluding the problems in the antigen coating and blocking process, it mainly exists in the design of enzyme-labeled secondary antibodies. The following is an example of anti-cat IgG secondary antibody. First, most traditional secondary antibodies are polyclonal antibodies, such as rabbit anti-cat IgG, which are obtained by immunizing rabbits with purified cat IgG. Due to the high homology of IgG sequences between mice and cats, it is not easy to produce IgG antibodies against cats. Therefore, there is no screening and purification of anti-cat IgG monoclonal antibodies in the existing technology. Cat IgG antibodies are composed of heavy chains and light chains (kappa or lambda). After immunizing rabbits, they can stimulate the animal immune system to produce antibodies against the heavy and light chains of cat IgG antibodies. The light chains of antibodies such as IgM, IgA, and IgE in cat serum are the same as those of IgG, that is, they are all kappa or lambda. In this way, when doing indirect ELISA to detect a certain type of coated antigen-specific cat IgG, due to the impurity of the secondary antibody (containing antibodies against heavy and light chains at the same time), false positive results or high background will be caused. Second, since the immune background of the animals (such as rabbits) used to prepare the secondary antibody is not very clear, rabbits themselves have antibodies against the coated antigen (caused by latent infection). When performing indirect ELISA testing, the antibodies against the coated antigen in the secondary antibody can directly bind to the coated antigen, resulting in false positive results or high background.

[0004] In view of the above shortcomings, this patent describes the preparation and application of anti-cat IgG antibody-specific monoclonal antibodies. Compared with the previously applied patent (CN116732045A), the antibody sequence of this application is clear and its various properties are more excellent. Compared with the antibodies prepared in the same batch, FG69 is very suitable as an indirect ELISA secondary antibody for determining the titer of cat FCV-specific IgG antibodies, which can reduce the background of the entire reaction system and amplify the signal of specific binding. Summary of the invention

[0005] The purpose of the present invention is to provide a method for separating and purifying cat IgG, preparing antigens for preparing anti-cat IgG monoclonal antibodies, including separation and purification of cat IgG, improvement of traditional monoclonal antibody technology, preparation and screening of anti-cat IgG monoclonal hybridoma cells, preparation of anti-cat IgG monoclonal antibodies, etc., to overcome the lack of secondary antibodies, i.e., anti-cat IgG monoclonal antibodies, in the prior art.

[0006] Furthermore, the present invention also provides a method for preparing a hybridoma cell strain of anti-cat IgG monoclonal antibody to solve the technical defect of the prior art that there is a lack of hybridoma cell strains of anti-cat IgG monoclonal antibody.

[0007] The above object of the present invention is achieved through the following technical solutions:

[0008] The method for preparing anti-cat IgG monoclonal antibody comprises the steps of separating and purifying cat IgG, immunizing BALB / C mice, fusing hybridoma cells, screening hybridoma cells, cloning hybridoma cells, preparing monoclonal antibody ascites, detecting the titer of monoclonal antibody ascites and preparing monoclonal antibody.

[0009] Furthermore, the present invention provides a mouse anti-cat IgG monoclonal antibody FG69, wherein the monoclonal antibody FG69 specifically binds to IgG1 (immunoglobulin of the G1 subclass) containing a kappa light chain constant domain.

[0010] The amino acid structure of the monoclonal antibody FG69 is:

[0011] The full length sequence of the heavy chain variable region is:

[0012] QVQLQQSAAELARPGASVKMSCKASGYTFTTYTIHWVKQRPGQGLEWIGYINPSSGYTEY NQKFKDKTTLTADKSSSTAYMQLSSLTSEDSTVYYCARSLITSAPWFVYWGQGTLVTVSA, where,

[0013] (Framework region 1) ntFR1: QVQLQQSAAELARPGASVKMSCKAS;

[0014] (Complementarity determining region 1) ntCDR1: GYTFTTYT;

[0015] (Framework region 2) ntFR2: IHWVKQRPGQGLEWIGY;

[0016] (Complementarity determining region 2) ntCDR2: INPSSGYT;

[0017] (Framework region 3) ntFR3: EYNQKFKDKTTLTADKSSSTAYMQLSSLTSEDSTVYYC;

[0018] (Complementarity determining region 3) ntCDR3: ARSLITSAPWFVY;

[0019] (Framework region 4) ntFR4: WGQGTLVTVSA;

[0020] The full length sequence of the light chain variable region is:

[0021] NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVP ARFSGSGSRTDFTLTIDPVEADDAATYYCQQNYEDPLTFGAGTKLELK;

[0022] in,

[0023] (Framework region 1) ntFR1: NIVLTQSPASLAVSLGQRATISCRAS;

[0024] (Complementarity determining region 1) ntCDR1: ESVDSYGNSF;

[0025] (Framework region 2) ntFR2: MHWYQQKPGQPPKLLIY;

[0026] (Complementarity determining region 2) ntCDR2: LAS;

[0027] (Framework region 3) ntFR3: NLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYC;

[0028] (complementarity determining region 3) ntCDR3: QQNYEDPLT;

[0029] (Framework region 4) ntFR4: FGAGTKLELK.

[0030] The nucleotide structure of the monoclonal antibody FG69 is:

[0031] The nucleotide sequence of the heavy chain variable region is:

[0032] CAGGTCCAGCTGCAGCAGTCTGCAGCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGA

[0033] TGTCCTGCAAGGCTTCTGGCTACACCTTTACTACCTACACGATTCACTGGGTAAAACAGA

[0034] GGCCTGGACAGGGTCTGGAATGGATTGGATACATTAATCCTAGCAGTGGATATACTGAAT

[0035] ACAATCAGAAATTCAAGGACAAGACCACATTGACTGCAGACAAATCCTCCAGCACAGC

[0036] CTACATGCAACTGAGCAGCCTGACATCTGAGGACTCTACGGTCTATTACTGTGCAAGATC

[0037] TCTCATTACTTCGGCTCCCTGGTTTGTTTATTGGGGCCAAGGGACTCTGGTCACTGTCTC

[0038] TGCA

[0039] in,

[0040] (Framework region 1) ntFR1:

[0041] CAGGTCCAGCTGCAGCAGTCTGCAGCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCTTCT;

[0042] (complementarity determining region 1) ntCDR1: GGCTACACCTTTACTACCTACACG;

[0043] (Framework region 2) ntFR2:

[0044] ATTCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGATAC;

[0045] (Complementarity determining region 2) ntCDR2: ATTAATCCTAGCAGTGGATATACT;

[0046] (Framework region 3) ntFR3:

[0047] GAATACAATCAGAAATTCAAGGACAAGACCACATTGACTGCAGACAAATCCTCCAGCAC AGCCTACATGCAACTGAGCAGCCTGACATCTGAGGACTCTACGGTCTATTACTGT;

[0048] (Complementarity determining region 3) ntCDR3: GCAAGATCTCTCATTACTTCGGCTCCCTGGTTTGTTTAT;

[0049] (Framework region 4) ntFR4:TGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA;

[0050] The full-length nucleotide sequence of the light chain variable region is:

[0051] AAATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCAC

[0052] CATATCCTGCAGAGCCAGTGAAAGTGTTGATAGTTATGGCAATAGTTTTATGCACTGGTA

[0053] CCAGCAGAAACCAGGACAGCCACCCAAACTCCTCATCTATCTTGCATCCAACCTAGAAT

[0054] CTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATT

[0055] GATCCTGTGGAGGCTGATGATGCTGCAACCTATTACTGTCAGCAAAATTATGAGGATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA;

[0056] in,

[0057] (Framework region 1) ntFR1:

[0058] AAATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGCAGAGCCAGT;

[0059] (Complementarity determining region 1) ntCDR1: GAAAGTGTTGATAGTTATGGCAATAGTTTT;

[0060] (Framework region 2) ntFR2:

[0061] ATGCACTGGTACCAGCAGAAACCAGGACAGCCACCCAAACTCCTCATCTAT;

[0062] (Complementarity determining region 2) ntCDR2: CTTGCATCC;

[0063] (Framework region 3) ntFR3:

[0064] AACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTT CACCCTCACCATTGATCCTGTGGAGGCTGATGATGCTGCAACCTATTACTGT;

[0065] (Complementarity determining region 3) ntCDR3: CAGCAAAATTATGAGGATCCGCTCACG;

[0066] (Framework region 4) ntFR4:TTCGGTGCTGGGACCAAGCTGGAGCTGAAA.

[0067] Furthermore, the present invention provides an application of mouse anti-cat IgG monoclonal antibody FG69, wherein the application is for detection for non-diagnostic or therapeutic purposes, preparation of detection kits or preparation of detection reagents.

[0068] Specifically, the detection is an indirect ELISA detection.

[0069] Furthermore, the indirect ELISA test is specifically as follows:

[0070] 1) Coating: Dilute the purified FCV VP1 protein to 2 μg / ml with coating solution (pH 9.6 carbonate buffer, the formula of which is: 0.85 g sodium carbonate, 1.4 g sodium bicarbonate, fixed to 500 ml), and coat it into the ELISA plate at 100 μl / well at 4°C overnight;

[0071] 2) Wash the plate 5 times with PBST (PBS + 5% Tween 20) buffer to remove unbound antigens and impurities, and pat the ELISA plate dry;

[0072] 3) Blocking: Add PBST buffer containing 1 w / v% BSA to each well for blocking, 200 μl / well, incubate at 37°C for 2 h;

[0073] 4) Same as step 2);

[0074] 5) Incubation with primary antibody: Select cat positive serum and negative serum and dilute them at 1:1000, add them to the ELISA plate, 100 μl / well, and incubate at 37°C for 1 hour;

[0075] 6) Same as step 2);

[0076] 7) Enzyme-labeled secondary antibody: dilute HRP-labeled mouse anti-cat IgG secondary antibody and rabbit anti-cat IgG secondary antibody at 1:5000 with PBS buffer, add them to the ELISA plate, 50 μl / well, and incubate at 37°C for 1 h;

[0077] 8) Same as step 2);

[0078] 9) Color development: Add Bio-Tech TMB color development solution, 100 μl / well, incubate at 37°C for 10 min;

[0079] 10) Termination: Use stop solution (2 M sulfuric acid) for termination, 50 μl / well, and detect at OD450nm;

[0080] 11) Analyze the data.

[0081] Furthermore, the present invention provides a kit containing HRP-labeled mouse anti-cat IgG monoclonal antibody FG69, the kit comprising a coating solution (pH 9.6 carbonate buffer, with a formula of 0.85 g sodium carbonate and 1.4 g sodium bicarbonate, fixed to 500 ml), a washing solution (PBST, with a formula of 8.0 g PBS NaCl, 2.9 g Na2HPO4·12H2O, 0.2 g KCl, 0.24 g KH2PO4, 5% Tween 20, fixed to 1 L), a blocking solution (1 w / v% BSA, diluted with PBST), a positive control serum, a negative control serum, and an enzyme-labeled secondary antibody (HRP-labeled mouse anti-cat IgG).

[0082] Furthermore, the present invention provides an application of the above-mentioned kit, wherein the application is a detection for non-diagnostic or therapeutic purposes, such as: pet food, environmental samples, trace elements, liquid biopsy, etc.

[0083] Beneficial Effects

[0084] The present invention prepares a new hybridoma cell line that produces anti-cat IgG monoclonal antibodies by preparing high-purity cat IgG as an antigen, purifies and prepares the anti-cat IgG monoclonal antibodies, and sequences them. Experimental results show that compared with previously obtained antibodies, the antibodies have better binding activity, provide antibodies for cat immunology detection, and lay a foundation for research on related virology, immunology, etc. with cats as objects. BRIEF DESCRIPTION OF THE DRAWINGS

[0085] Figure 1 This is the sequence comparison of E. coli codons of cat IgG protein before and after optimization (the black box indicates the changed sequence);

[0086] Figure 2 The heavy chain and light chain variable region sequences were obtained by PCR amplification, wherein A is the electrophoresis diagram of the heavy chain PCR amplification product, wherein M is a marker, 1-2 are the heavy chain PCR products, and 3 is a positive control; B is the electrophoresis diagram of the light chain PCR amplification product, wherein M is a marker, 1-2 are the light chain PCR products, and 3 is a positive control;

[0087] Figure 3 The electrophoresis diagram of the recombinant bacteria PCR, A is the electrophoresis diagram of the heavy chain PCR bacteria test, M is a marker, 1-8 are the heavy chain PCR products, and 3 is a positive control; B is the electrophoresis diagram of the light chain PCR bacteria test, M is a marker, 1-8 are the light chain PCR products;

[0088] Figure 4 For indirect ELISA result analysis. DETAILED DESCRIPTION

[0089] The substantial content of the present invention is further described below with reference to the accompanying drawings using embodiments of the present invention, but the present invention is not limited thereto.

[0090] Example 1 Screening and identification of mouse anti-cat IgG monoclonal antibody FG69

[0091] Referring to the contents described in the prior application CN116732045A of the present applicant, the purified cat IgG protein ( Figure 1 ), immunizing BALB / C mice, fusing hybridoma cells, screening hybridoma cells, cloning hybridoma cells, preparing monoclonal antibody ascites, detecting the titer of monoclonal antibody ascites, and obtaining monoclonal antibodies.

[0092] Take hybridoma cells (5×10 6 ), the total RNA of hybridoma cell lines was extracted by Trizol reagent method, and a small amount was taken for quantification by UV spectrophotometer and 1% formaldehyde denaturing agarose gel electrophoresis.

[0093] According to the kit instructions, total RNA was used as a template and oligo(dT) 15 As primer, use SuperScriptII reverse transcriptase to synthesize the first strand of cDNA. After reverse transcription, add RNase to hydrolyze RNA so that the product contains only the first strand of cDNA. Use SNAP centrifugal column to purify the first strand of cDNA.

[0094] Primers were designed based on the conserved sites of the mouse antibody gene sequence in GENEBANK, and cDNA was used as a template to amplify the variable region genes of the antibody light and heavy chains. The PCR program was: 94°C for 30s, 58°C for 1min, 72°C for 1min, 30 cycles of amplification, and finally 72°C for 10min. After the PCR product was separated by 1% (weight percentage) agarose gel electrophoresis, the DNA fragment was purified and recovered using a kit, connected to the vector pMD18-T, transformed into Escherichia coli DH5α competent cells, and the positive clones were picked and sent to Shanghai Sunny Biotechnology Co., Ltd. for sequencing.

[0095] The sequences of the primers are: the heavy chain variable region primer is 5'-AGGTSMARGTGCAGSCGTCWCC-3' (22mer) and 5'-TGACCAGACGGAGTCCGGTGTCCCTTCCGGCC-3' (32mer), wherein S, M, R and W are degenerate bases, M = A / C, R = A / G, S = C / G, W = A / T,

[0096] The light chain variable region primers were 5′-CAGATTGAGCACTCCCAGTCTGGTCGC-3′ (24mer) and 5′-CCGTCTTAGTCCCAGCTGTCTCGC-3′ (24mer).

[0097] The amplified product was identified by agarose gel electrophoresis (1.5%). Figure 2 After purification using the PCR product purification kit (Omega), the target fragment was cloned into the T vector ( Figure 3 ), sequencing analysis.

[0098] The results showed that the amino acid structure of the monoclonal antibody FG69 is:

[0099] The full length sequence of the heavy chain variable region is:

[0100] QVQLQQSAAELARPGASVKMSCKASGYTFTTYTIHWVKQRPGQGLEWIGYINPSSGYTEY

[0101] NQKFKDKTTLTADKSSSTAYMQLSSLTSEDSTVYYCARSLITSAPWFVYWGQGTLVTVSA(SEQ IDNO.1), where,

[0102] (Framework region 1) ntFR1: QVQLQQSAAELARPGASVKMSCKAS (SEQ ID NO. 2);

[0103] (Complementarity determining region 1) ntCDR1: GYTFTTYT (SEQ ID NO. 3);

[0104] (Framework region 2) ntFR2: IHWVKQRPGQGLEWIGY (SEQ ID NO. 4);

[0105] (Complementarity determining region 2) ntCDR2: INPSSGYT (SEQ ID NO. 5);

[0106] (Framework region 3) ntFR3: EYNQKFKDKTTLTADKSSSTAYMQLSSLTSEDSTVYYC (SEQ ID NO. 6);

[0107] (Complementarity determining region 3) ntCDR3: ARSLITSAPWFVY (SEQ ID NO. 7);

[0108] (Framework region 4) ntFR4: WGQGTLVTVSA (SEQ ID NO. 8);

[0109] The full length sequence of the light chain variable region is:

[0110] NIVLTQSPASLAVSLGQRATISCRASESVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVP ARFSGSGSRTDFTLTIDPVEADDAATYYCQQNYEDPLTFGAGTKLELK(SEQ ID NO.9);

[0111] in,

[0112] (Framework region 1) ntFR1: NIVLTQSPASLAVSLGQRATISCRAS (SEQ ID NO. 10);

[0113] (Complementarity determining region 1) ntCDR1: ESVDSYGNSF (SEQ ID NO. 11);

[0114] (Framework region 2) ntFR2: MHWYQQKPGQPPKLLIY (SEQ ID NO. 12);

[0115] (Complementarity determining region 2) ntCDR2: LAS (SEQ ID NO. 13);

[0116] (Framework region 3) ntFR3: NLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYC (SEQ ID NO. 14);

[0117] (Complementarity determining region 3) ntCDR3: QQNYEDPLT (SEQ ID NO. 15);

[0118] (Framework region 4) ntFR4: FGAGTKLELK (SEQ ID NO. 16).

[0119] The nucleotide structure of the monoclonal antibody FG69 is:

[0120] The nucleotide sequence of the heavy chain variable region is:

[0121] CAGGTCCAGCTGCAGCAGTCTGCAGCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGA

[0122] TGTCCTGCAAGGCTTCTGGCTACACCTTTACTACCTACACGATTCACTGGGTAAAACAGA

[0123] GGCCTGGACAGGGTCTGGAATGGATTGGATACATTAATCCTAGCAGTGGATATACTGAAT

[0124] ACAATCAGAAATTCAAGGACAAGACCACATTGACTGCAGACAAATCCTCCAGCACAGC

[0125] CTACATGCAACTGAGCAGCCTGACATCTGAGGACTCTACGGTCTATTACTGTGCAAGATC

[0126] TCTCATTACTTCGGCTCCCTGGTTTGTTTATTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA(SEQID NO.17);

[0127] in,

[0128] (Framework region 1) ntFR1:

[0129] CAGGTCCAGCTGCAGCAGTCTGCAGCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCTTCT (SEQ ID NO. 18);

[0130] (Complementarity determining region 1) ntCDR1: GGCTACACCTTTACTACCTACACG (SEQ ID NO. 19);

[0131] (Framework region 2) ntFR2:

[0132] ATTCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGATAC (SEQ ID NO. 20);

[0133] (Complementarity determining region 2) ntCDR2: ATTAATCCTAGCAGTGGATATACT (SEQ ID NO. 21);

[0134] (Framework region 3) ntFR3:

[0135] GAATACAATCAGAAATTCAAGGACAAGACCACATTGACTGCAGACAAATCCTCCAGCAC AGCCTACATGCAACTGAGCAGCCTGACATCTGAGGACTCTACGGTCTATTACTGT (SEQ ID NO. 22);

[0136] (Complementarity determining region 3) ntCDR3: GCAAGATCTCTCATTACTTCGGCTCCCTGGTTTGTTTAT (SEQ ID NO. 23);

[0137] (Framework region 4) ntFR4: TGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID NO. 24);

[0138] The full-length nucleotide sequence of the light chain variable region is:

[0139] AAATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCAC

[0140] CATATCCTGCAGAGCCAGTGAAAGTGTTGATAGTTATGGCAATAGTTTTATGCACTGGTA

[0141] CCAGCAGAAACCAGGACAGCCACCCAAACTCCTCATCTATCTTGCATCCAACCTAGAAT

[0142] CTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATT

[0143] GATCCTGTGGAGGCTGATGATGCTGCAACCTATTACTGTCAGCAAAATTATGAGGATCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA (SEQ ID NO. 25);

[0144] in,

[0145] (Framework region 1) ntFR1:

[0146] AAATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGCAGAGCCAGT (SEQ ID NO. 26);

[0147] (Complementarity determining region 1) ntCDR1: GAAAGTGTTGATAGTTATGGCAATAGTTTT (SEQ ID NO. 27);

[0148] (Framework region 2) ntFR2:

[0149] ATGCACTGGTACCAGCAGAAACCAGGACAGCCACCCAAACTCCTCATCTAT(SEQ ID NO.28);

[0150] (Complementarity determining region 2) ntCDR2: CTTGCATCC (SEQ ID NO. 29);

[0151] (Framework region 3) ntFR3:

[0152] AACCTAGAATCTGGGGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTAGGACAGACTT CACCCTCACCATTGATCCTGTGGAGGCTGATGATGCTGCAACCTATTACTGT (SEQ ID NO. 30);

[0153] (Complementarity determining region 3) ntCDR3: CAGCAAAATTATGAGGATCCGCTCACG (SEQ ID NO. 31);

[0154] (Framework region 4) ntFR4: TTCGGTGCTGGGACCAAGCTGGAGCTGAAA (SEQ ID NO. 32).

[0155] Example 2 Indirect ELISA method was used to detect the titer and specificity of the purified antibody

[0156] The specific detection methods are as follows:

[0157] 1) Coating: Use coating solution (pH 9.6 carbonate buffer, the formula is: sodium carbonate 0.85g, sodium bicarbonate 1.4g, dilute to 500ml) to dilute the purified cat IgG protein prepared in this laboratory (see CN116732045A) to 2μg / ml, and coat it into the ELISA plate at 100μl / well, and coat it at 4℃ overnight. Wash the plate 5 times with PBST buffer to remove unbound antigens and impurities, and pat the ELISA plate dry.

[0158] 2) Blocking: Add PBST buffer containing 1 w / v% BSA to each well for blocking, 200 μl / well, incubate at 37°C for 2 h. Wash the plate 5 times with PBST buffer and pat dry the ELISA plate.

[0159] 3) Detection: FG69 anti-cat IgG monoclonal antibody and the antibody in the prior application CN116732045A were selected and added to the ELISA plate, 100 μl / well, incubated at 37° C. for 1 h. The plate was washed 5 times with PBST buffer and the ELISA plate was patted dry.

[0160] 4) Add enzyme-labeled secondary antibody: Dilute HRP-labeled goat anti-mouse and goat anti-rabbit antibodies 5000 times with PBS buffer, add to the ELISA plate, 50 μl / well, incubate at 37°C for 1 hour. Wash the plate 5 times with PBST buffer and pat the plate dry.

[0161] 5) Color development: Add TMB color development solution for color development, 100 μl / well, incubate at 37°C for 10 min; stop with 2M sulfuric acid stop solution, 50 μl / well, and detect at OD450nm.

[0162] Test results are shown in Figure 4 ,pass Figure 4 It can be found that the pure anti-cat IgG titer prepared by the present invention is higher than the control, indicating that the purified antibody has good specificity. After repeated experiments, it is proved that the antibody purified by this method has high titer and good specificity. The results confirm that the results detected by commercial antibodies are more false positive or false negative, and there are more noises, which cannot correctly reflect the actual situation, while the results detected by the antibodies of the present application are more accurate, more sensitive and more targeted. Whether compared with the commonly used ELISA kit or the gold standard fluorescent neutralization antibody method, the monoclonal antibody obtained by the present invention is simple to operate, fast to detect, and realizes quantitative detection, which is conducive to promotion and use.

[0163] The above description is only a preferred embodiment of the present invention and does not impose any formal or substantial limitation on the present invention. Any technician familiar with the profession can make use of the technical contents disclosed above without departing from the scope of the technical solution of the present invention, and any slight changes, modifications and evolutions made by equivalent changes are all equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention still fall within the scope of the technical solution of the present invention.

Claims

1. An anti-cat IgG monoclonal antibody or an antigen-binding fragment thereof, the antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain complementary determining region VH CDR1, VH CDR2 and VH CDR3 as shown in SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 7, and the light chain variable region comprises a light chain complementary determining region VL CDR1, VL CDR2 and VL CDR3 as shown in SEQ ID NO: 11, SEQ ID NO: 13, or SEQ ID NO:

15.

2. An anti-cat IgG monoclonal antibody or an antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

9.

3. A nucleic acid molecule encoding an anti-cat IgG monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1-2. A vector comprising the nucleic acid molecule according to claim 3 . 5 . An expression cell comprising the nucleic acid molecule according to claim 3 or the vector according to claim 4 .

6. Use of an anti-cat IgG monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1-2 in the preparation of a reagent for detecting cat IgG.

7. A kit for detecting cat IgG, comprising the anti-cat IgG monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 2 and instructions for use.

Citation Information

Patent Citations

  • Anti-cat IgG monoclonal antibody and application thereof

    CN116732045A

  • Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin

    CA2022959A1

  • Anti-feline herpes virus-1 recombinant antibody and gene fragment coding for said antibody

    CA2150346C

  • Human anti-PD-1, PD-L1, and PD-L2 antibodies, and application thereof

    CN108484767A

  • Celine calicivirus antigen test strip detection kit

    CN116024179A